Jose Herazo-Maya Archives - USF Health News https://hscweb3.hsc.usf.edu/blog/tag/jose-herazo-maya/ USF Health News Wed, 19 Jan 2022 14:13:25 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 USF Health remembers Timothy Ubben, who gave $5 million to fight pulmonary fibrosis https://hscweb3.hsc.usf.edu/blog/2021/12/16/usf-health-remembers-timothy-ubben-who-gave-5-million-to-fight-pulmonary-fibrosis/ Thu, 16 Dec 2021 22:37:20 +0000 https://hscweb3.hsc.usf.edu/?p=35764 On Monday, Dec. 13, the University of South Florida announced a $5 million gift made by Naples philanthropist Timothy Ubben in November to create the Ubben Family Center […]

]]>

On Monday, Dec. 13, the University of South Florida announced a $5 million gift made by Naples philanthropist Timothy Ubben in November to create the Ubben Family Center for Pulmonary Fibrosis.

Sadly, that night he passed away at the age of 84.

Sharon and Timothy Ubben with Dr. Jose D. Herazo-Maya.

Housed in the USF Health Morsani College of Medicine, the center will increase research to fight pulmonary fibrosis, a disease that causes lung scarring.

Through the final year of his personal battle with pulmonary fibrosis, Ubben wanted to help future patients have better options for fighting the condition. In February, USF announced Ubben’s first gift of $1 million to establish the Ubben Family Pulmonary Research Laboratory, led by Dr. Jose D. Herazo-Maya, associate chief of the Division of Pulmonary, Critical Care and Sleep Medicine and director of the Ubben Program for Pulmonary Fibrosis Research in the USF Health Morsani College of Medicine.

“Pulmonary fibrosis doesn’t get popular support or much research funding,” Ubben said in November. “I probably won’t be around to benefit from the results of Dr. Herazo’s research, but hopefully other pulmonary fibrosis patients will. I want him to find the cure, and I want him to do it at USF Health.”

Herazo began caring for Ubben as his pulmonologist in Naples, and he continued providing care after he moved to Tampa to join USF in January 2021.

“Mr. Ubben was a wonderful friend, and it is humbling to receive such support to lead this critical research,” Herazo said. “Pulmonary fibrosis is a devastating disease, and Mr. Ubben’s generous gift will help us better understand its root causes so we can expedite the discovery of new tests and treatments.”

“We are saddened by the news of Mr. Ubben’s passing,” said Dr. Charles Lockwood, USF Health senior vice president and dean of the Morsani College of Medicine. “We will do our best to honor his generosity and legacy as we work to find new therapies for pulmonary fibrosis patients.”

“It is inspiring how even while he was dealing with his own health challenges, Mr. Ubben was determined to help future patients through his philanthropy,” USF Foundation CEO Jay Stroman said. “We extend our deepest condolences to his wife, family and friends.”

Ubben founded Lincoln Capital Management, a successful Chicago-based investment firm, in 1967. Since retiring in 1999, he dedicated his time, resources and expertise in board leadership to nonprofit and educational organizations.

In lieu of flowers, the family requests donations be made to the USF Ubben Pulmonary Fibrosis Fund at usf.to/ubben or by calling Arty Giallourakis at 813-974-3676.



]]>
USF Health physician-scientist pinpoints genes to predict lung fibrosis outcomes https://hscweb3.hsc.usf.edu/blog/2021/12/06/usf-health-physician-scientist-pinpoints-genes-to-predict-lung-fibrosis-outcomes/ Mon, 06 Dec 2021 22:23:28 +0000 https://hscweb3.hsc.usf.edu/?p=35581 Dr. Jose Herazo-Maya’s research may help identify new treatments to improve survival in patients with idiopathic pulmonary fibrosis and severe COVID-19   Caring for patients struggling to breathe […]

]]>

Dr. Jose Herazo-Maya’s research may help identify new treatments to improve survival in patients with idiopathic pulmonary fibrosis and severe COVID-19

 

Caring for patients struggling to breathe drives Dr. Jose Herazo-Maya’s research to find effective treatments for pulmonary fibrosis — an incurable, debilitating and often fatal disease that causes progressive lung scarring.

“The primary goal of our research team is to identify genes that predict survival (a low vs. high risk of dying) in patients with lung fibrosis,” said Herazo-Maya, MD, an associate professor and associate chief of pulmonary, critical care and sleep medicine at the USF Health Morsani College of Medicine. “We believe that if you target these genes, you can develop new treatments to help improve survival in these patients.”

The only two drugs currently approved to treat patients with idiopathic pulmonary fibrosis (pirfenidone and nintedanib) may help slow disease progression, but they do not stop lung scarring or prolong survival, and adverse effects can occur in up to half of people with IPF. Lung transplantation can improve survival, but organs are limited and not every patient with pulmonary disease is eligible for the complex surgery.

CT scans of (Above) normal lungs and (Below) lungs with  idiopathotic pulmonary fibrosis, characterized by scars and cysts. Images courtesy of Dr. Jose Herazo-Maya, USF Health

Pulmonary fibrosis is a disease in which the tissue in and between the air sacs of the lungs (alveoli) becomes damaged and scarred. As the tissue (interstitium) thickens and stiffens, it affects the ability to breathe and get enough oxygen into the bloodstream. While toxic environmental exposures, smoking and certain other diseases have been associated with pulmonary fibrosis, in most cases the cause is unknown (idiopathic). Median survival for patients diagnosed with idiopathic pulmonary fibrosis (IPF) is three to five years.

“IPF is a devasting disease that needs better therapeutic options to improve quality of life and save lives,” Dr. Herazo-Maya said. “For me, taking care of these patients is a constant reminder that we need to do better.”

A return to academic medicine

Dr. Herazo-Maya joined USF Health in January 2021 from NCH Healthcare System in Naples, Fla., where he spent nearly four years directing a growing Interstitial Lung Disease Program. Before that, the physician-scientist was an assistant professor at Yale University School of Medicine. He is an expert in genomics, with a focus on studying how gene expression influences immunity and its association with disease progression and outcomes.

USF Health physician scientist Jose Herazo-Maya, MD, (far right) in his USF Health Heart Institute laboratory with his research team. Photographed (l to r) are Carole Perrot, PhD; Bochra Tourki, PhD; Alyssa Arsenault, LPN; and Brenda Juan-Guardela, MD. — Photo by Allison Long, USF Health Communications and Marketing

At Yale Dr. Herazo-Maya was part of team that discovered a gene expression signature in blood that reliably forecasts the likelihood of mortality and poor outcomes from IPF. The team subsequently led an international study that validated this risk profile based on 52 genes. He was among the inventors on the patent for the IPF gene risk profile, since acquired by a global company seeking to develop the scientific breakthrough into a simple blood test to be used for patient care.

Dr. Herazo-Maya returned to academic medicine after several years of private practice in Naples, in part he says because he was frustrated by the lack of research progress to identify pulmonary fibrosis treatment options. A surge in patients battling severe lung scarring from COVID-19 complications also prompted his decision to recommit to translating discoveries from the laboratory back to the patient bedside.

Soon after arriving at the USF Health Heart Institute last year, Dr. Herazo-Maya quickly began building a pulmonary fibrosis research program with the generous support of a $1 million gift made by philanthropist Timothy Ubben to the USF Foundation. (In December 2021, Mr. Ubben gave an additional $5 million to create the Ubben Family Center for Pulmonary Fibrosis that will accelerate research leading to new tests and treatments for patients.)

Dr. Herazo-Maya, a member of the pulmonary and critical care team at Tampa General Hospital, also treats patients at the TGH Center for Advanced Lung Disease — including those being evaluated for lung transplant. Along with fellow USF Health pulmonologists Dr. Kapilkumar Patel and Dr. Debabrata Bandyopadhyay at this leading TGH Center, Dr. Herazo-Maya is an investigator for clinical trials testing potential new drugs to treat lung fibrosis.

Bochra Tourki, PhD, looks at a computer slide of immune cells from the lung tissue of a COVID-19 patient with pulmonary fibrosis. – Photo by Allison Long

The impact of witnessing “air hunger”

From the start of his medical career, Dr. Herazo-Maya was interested in both critical care and science. While conducting a postdoctoral fellowship at the University of Pittsburgh School of Medicine’s Simmons Center for Interstitial Lung Disease, he was invited by his faculty mentor and center director Nafali Kaminski, MD, to accompany a group of the center’s patients, physicians, and scientists on a boat trip along the city’s rivers.

“I remember the patients using oxygen had a very hard time getting into the boat. They could not even take a few steps without becoming short of breath,” Dr. Herazo-Maya said. “Seeing how those patients struggled to breathe – their feeling of air hunger – had a big impact on me wanting to take care of them.”

While certain patients with IPF can live well for years, others develop worsening disease and die quickly. No prognostic tool yet exists to tell doctors which patients will experience rapid progression of pulmonary fibrosis, and which will progress slowly. But Dr. Herazo-Maya and colleagues are working on a molecular-level test to do just that.

A tool to predict the clinical course of IPF or any other type of lung fibrosis could help patients and clinicians make better informed decisions about care, Dr. Herazo-Maya said. “For instance, if a rapid test indicated that a patient’s genetic predisposition to mortality was high, they might need to get to the hospital to receive more aggressive medical care, and possibly be evaluated for lung transplant while they are still relatively healthy enough to withstand transplant surgery.”

Dr. Herazo-Maya (far left) consults with (l to r) staff scientist Carole Perot, PhD; postdoctoral scholar Bochra Tourki, PhD; and clinical research coordinator Alyssa Arsenault, LPN. – Photo by Allison Long

Genomic risk prediction can also increase opportunities for drug discovery, he said. “Each one of the genes we analyze is a potential drug target. We can study them in the lab to understand how they work and possibly come up with novel therapies.”

Pivoting genomic research to COVID-19

As the COVID-19 pandemic unfolded in 2020, pulmonologists and other critical care clinicians were inundated by patients in respiratory distress.

As he helped treat the influx of hospitalized patients, Dr. Herazo-Maya noticed that, like IPF, severe COVID-19 could also damage the lung interstitium leading to severe scarring. He thought about finding more precise ways to distinguish between symptomatic individuals likely to recover at home with appropriate monitoring and those likely to end up in the intensive care unit (ICU) and die. A prognostic tool capable of detecting which patients were apt to do worse before they became seriously ill could help health care providers better allocate limited resources like ICU beds and ventilators, tailor interventions, and potentially save lives.

“At the time investigators were scrambling to identify gene profiles predictive of COVID-19 outcomes,” Dr. Herazo-Maya said. “So, our basic question was ‘Can we repurpose a gene risk profile known to predict mortality in IPF to predict mortality in those infected with a new coronavirus that can cause lung fibrosis as well?’”

The preliminary answer appears to be yes.

Dr. Herazo-Maya’s computer monitor displays heat maps depicting clusters of COVID-19 subjects identified as having a low vs. high risk of mortality (Below), based on a gene expression signature in blood. The recent research showed that a previously validated technique for predicting idiopathic lung fibrosis outcomes could be repurposed for COVID-19. – Photo by Allison Long | Heat map image courtesy of Dr. Herazo-Maya, USF Health

Earlier this year, a multicenter retrospective study led by USF Health’s Dr. Herazo-Maya demonstrated that a 50-gene signature associated with a high risk of dying from IPF can also predict poor outcomes (ICU admissions, mechanical ventilation, and death) in patients with COVID-19. The findings were reported in EBioMedicine, a publication of THE LANCET.

More studies are needed, but researchers and clinicians may soon be able to apply the gene risk profile to help advance the care of both COVID-19 and IPF patients, Dr. Herazo-Maya said. His laboratory is currently developing a blood test, based on a more selective group of the 50 genes, that can be easily applied in clinical practice.

Two distinct diseases, same gene risk profile

The overlapping gene expression profiles for COVID-19 and IPF look remarkably similar, Dr. Herazo-Maya said. “That suggests there are immune pathways shared between these two diseases.”

Using single-cell gene analyses, Dr. Herazo-Maya has identified specific immune cells – monocytes, neutrophils, and dendritic cells — as the primary source of gene expression changes in the high-risk COVID-19 gene profile. Interestingly, he said, monocytes can give rise to macrophages involved in triggering scar formation.

Brenda Perrot, PhD, works on an experiment.

Dr. Herazo-Maya received his MD degree from the University of Cartagena School of Medicine in Colombia. He completed a research fellowship in interstitial lung disease and residency training in internal medicine at the University of Pittsburgh School of Medicine. Specializing in pulmonary and critical care, he conducted postdoctoral training in genomics, computational biology, bioinformatics and molecular biology at Yale and Pittsburgh universities.

The Robert Wood Johnson Foundation and the Pulmonary Fibrosis Foundation funded his research in the past, and his current work is supported by the USF Foundation-Ubben Family Fund.

Dr. Herazo-Maya has published numerous peer-reviewed papers, including in such high-impact journals as the Nature Medicine, the Journal of Clinical Investigation, Lancet Respiratory Medicine, Science Translational Medicine and the American Journal of Respiratory and Critical Care Medicine. He is the coauthor of several book chapters on topics ranging from biomarkers in assessing and managing IPF to applying personalized medicine (‘omics) to lung fibrosis.

Dr. Herazo-Maya and his wife Dr. Brenda Juan-Guardela (right), assistant professor of medicine at USF Health and medical director of Respiratory Care Services at TGH, have collaborated on pulmonary fibrosis research throughout their medical careers. – Photo by Allison Long

Some things you may not know about Dr. Herazo-Maya

If he did not become a physician and researcher, Dr. Herazo-Maya says he would have been a marine biologist. Growing up near the beach in Cartagena, he snorkeled and was “fascinated by all the sea creatures.”

Dr. Herazo-Maya is married to pulmonologist Brenda Juan-Guardela, MD, an assistant professor of medicine at USF Health Morsani College of Medicine and medical director of Respiratory Care Services at TGH. They met in medical school, trained in the same laboratory as postdoctoral scholars, and continue to collaborate on pulmonary fibrosis research. They live in Tampa with their two sons Christian, 6, and Lucas, 4.

In his spare time, Dr. Herazo-Maya enjoys playing soccer and baseball with his sons in their yard and watching their youth soccer league games.

 



]]>
Gene profile in blood predicts risk of poor outcomes, death for patients with COVID-19 https://hscweb3.hsc.usf.edu/blog/2021/06/20/gene-profile-in-blood-predicts-risk-of-poor-outcomes-death-for-patients-with-covid-19/ Mon, 21 Jun 2021 02:46:42 +0000 https://hscweb3.hsc.usf.edu/?p=34251 A previously validated gene profile in blood that predicts idiopathic pulmonary fibrosis mortality was repurposed to assess the likelihood of COVID-19 survival, a USF Health-led study reports Tampa, […]

]]>

A previously validated gene profile in blood that predicts idiopathic pulmonary fibrosis mortality was repurposed to assess the likelihood of COVID-19 survival, a USF Health-led study reports

Tampa, FL (June 20, 2021) — A blood gene profile associated with a high risk of dying from a severe lung disease can also predict poor outcomes in patients with COVID-19, a multicenter retrospective study led by the University of South Florida Health (USF Health) demonstrated. The risk profile based on 50 genes could help customize how COVID-19 is treated, improve allocation of limited health care resources such as intensive care beds and ventilators, and potentially save lives.

Idiopathic pulmonary fibrosis (IPF), a disease of unknown cause, affects the lung interstitium or the space between the lung sacs and the bloodstream, leading to severe lung scarring. Severe COVID-19 can also damage the lung interstitium leading to severe lung scarring.

“Our study identified at the molecular level, a gene risk profile that predicts worse COVID-19 outcomes before the patient becomes severely ill,” said principal investigator Jose Herazo-Maya, MD, an associate professor and associate chief of pulmonary, critical care and sleep medicine at the USF Health Morsani College of Medicine. “That means every patient with COVID-19 could potentially get a blood test that could tell us if they are at high or low risk of dying… And if we know in advance who will likely end up in the ICU and who will likely do well recovering at home with appropriate monitoring, we can tailor our interventions to individual patients based on their level of risk.”

The USF Health study appeared online June 20 in EBioMedicine, a publication of THE LANCET. It builds upon previous genomic research by Dr. Herazo-Maya and colleagues at Yale School of Medicine. In 2017, they led an international team that studied and validated a gene expression signature in the blood that reliably forecasts the likelihood of IPF mortality. (Certain patients with lung scarring can live well for years, while others develop worsening disease and die quickly from IPF.)

The study’s principal investigator was Jose Herazo-Maya, MD, associate professor of medicine and associate division chief of USF Health Pulmonary, Critical Care and Sleep Medicine. | Photo by Allison Long,  USF Health Communications and Marketing

As the COVID-19 pandemic unfolded, “the basic question we had was ‘Can we repurpose the gene signature known to predict mortality in a fibrotic lung disease to predict mortality in those infected with a new coronavirus that can cause lung fibrosis as well?” said the EBioMedicine paper lead author Brenda Juan-Guardela, MD, assistant professor of medicine at the USF Health Morsani College of Medicine and medical director of Respiratory Care Services at Tampa General Hospital (TGH). “To the best of our knowledge, this study is the first to compare overlapping immune gene profiles in COVID-19 and IPF, which were remarkably similar.”

The USF Health-led team analyzed gene expression patterns of 50 genes known to predict IPF mortality in three COVID-19 cohorts and two IPF cohorts. The researchers used a molecular scoring system to distinguish between high versus low-risk gene profiles in all five cohorts.

Among their findings:

  • In the COVID-19 validation cohorts, a 50-gene high risk profile was linked to greater risk of ICU admission, mechanical ventilation, and in-hospital death.
  • The researchers also performed single-cell, gene expression analyses and identified specific immune cells — monocytes, neutrophils, and dendritic cells – as the primary source of gene expression changes in the high-risk, COVID-19 gene profile. This finding suggests COVID-19 and IPF may share common innate and adaptive immune responses that trigger lung scarring.
  • The 50-gene risk profile in COVID-19 can also predicts mortality in IPF at the exact same threshold.

Lead author Brenda Juan-Guardela, MD, assistant professor of medicine at the USF Health Morsani College of Medicine and medical director of Respiratory Care Services at TGH

At TGH, Dr. Herazo-Maya treats previously hospitalized COVID-19 patients who come to the Center for Advanced Lung Disease with severe lung fibrosis; some are being evaluated for lung transplantation. “Even though coronavirus cases are dropping, that doesn’t mean all the patients will recover without complications,” he said. “We’re starting to see the damaging, long-term effects in the lungs of some COVID-19 survivors.”

While more studies are needed, researchers and clinicians may soon be able to apply the gene risk profiles to help advance the care of both COVID-19 and IPF patients, Dr. Herazo-Maya said. His laboratory is currently developing a blood test, based on these genes, that can be easily applied in clinical practice to predict poor disease outcomes.

Besides outcome prediction, the identification of 50-gene risk profiles may also have significant therapeutic potentials.  For example, a 10-day regimen of the steroid dexamethasone, a drug that suppresses the immune system, has been shown to increase survival of patients hospitalized with COVID-19. Immunosuppressant drugs have been essentially discontinued for IPF treatment because they increase mortality when given at high doses and in combination over long periods, Dr. Herazo-Maya said. “But perhaps we could investigate the use of dexamethasone or a similar steroid treatment for a short period of time in a subgroup of IPF patients with a 50-gene high risk profile, using the principle of precision or personalized medicine.”

The 50-gene high risk profile may also support the rationale to investigate the use of targeted IPF antifibrotic medications, which slow the rate of lung scarring, to prevent short and long-term sequelae of COVID-19, he added.

Heat maps depict clustering of COVID-19 subjects based on 50-gene risk profiles (High versus Low) determined by SAMS in Discovery (a) and Validation cohorts (b). The image, courtesy of Jose Herazo-Maya, first appeared online 20 June 2021 in EBioMedicine, Vol. 69. Full caption available for this Figure 1 at: www.sciencedirect.com/science/article/pii/S2352396421002322

USF Health’s Gaetane Michaud, MD, professor of medicine and chief of pulmonary, critical care and sleep medicine, was a paper coauthor. The research was supported by the Ubben Pulmonary Fibrosis Fund-USF Foundation, National Institute for Health Clinician Scientist Fellowship, Action for Pulmonary Fibrosis Mike Bray Fellowship, and the National Heart, Lung, and Blood Institute.

 



]]>
$1 million gift to USF will advance lung research https://hscweb3.hsc.usf.edu/blog/2021/02/17/1-million-gift-to-usf-will-advance-lung-research/ Wed, 17 Feb 2021 17:01:57 +0000 https://hscweb3.hsc.usf.edu/?p=33478 The gift will fund USF Health research into pulmonary fibrosis TAMPA, Fla. (Feb. 17, 2021) — The University of South Florida announced Feb 17, 2021, a $1 million […]

]]>

The gift will fund USF Health research into pulmonary fibrosis

TAMPA, Fla. (Feb. 17, 2021) — The University of South Florida announced Feb 17, 2021, a $1 million gift to the USF Foundation that will fund research to detect and prevent severe lung scarring. Philanthropist Timothy Ubben made the gift to support research at USF led by his doctor, Jose D. Herazo-Maya, USF Health’s newly appointed associate chief of pulmonary, critical care and sleep medicine.

“We can make a powerful impact when patients and physicians unite to bring big ideas to reality,” USF President Steve Currall said. “This generous gift will help the University of South Florida advance innovative testing and treatment of the toughest cases of devastating lung conditions, ultimately saving lives.”

“We are delighted with this confluence of vision, talent and philanthropy,” said Dr. Charles Lockwood, USF Health senior vice president and dean of the Morsani College of Medicine. “The timing of Mr. Ubben’s gift is helping us to rapidly launch this important research to fight devastating lung conditions.”

Ubben founded Lincoln Capital Management, a successful Chicago-based investment firm, in 1967. Since retiring in 1999, he has dedicated his time, resources and expertise in board leadership to nonprofit and educational organizations.

“I have been discouraged in the lack of progress in alleviating pulmonary fibrosis in patients,” said Ubben. “This funding will support research to better understand and find assistance in the fight against this disease.”

“Certain patients with lung scarring can live well for years while others develop disease exacerbations and die quickly from the disease,” said Dr. Herazo, who also described Ubben as a good friend. “Tim is intellectually curious and has good knowledge about medical research and clinical trials — I enjoy talking with him about science and ways to improve disease.”

While at Yale, Dr. Herazo served on a team that discovered a gene signature in blood that predicted mortality from idiopathic pulmonary fibrosis (IPF). He now leads a USF Health research team working to develop a blood test based on gene expression that will help identify patients at risk of severe disease before they clinically deteriorate.

“Mr. Ubben’s generous gift is providing hope and momentum in the fight against pulmonary disease,” said USF Foundation CEO Jay Stroman. “The potential benefit this donor-funded research could have on health care systems everywhere is astounding.”

Dr. Herazo, who joined USF Health last month, is already putting Ubben’s gift to work as he outfits the Ubben Family Pulmonary Research Laboratory in the new USF Health Heart Institute space in downtown Tampa. He is building a research team including other USF physician scientists, biostatisticians, clinical and basic scientists.



]]>